• Therapeutics
  • This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. (pitchengine.com)
  • urology
  • citation needed] Newer techniques involving lasers in urology have emerged in the last 5-10 years, starting with the VLAP technique involving the Nd:YAG laser with contact on the prostatic tissue. (wikipedia.org)
  • clinical
  • The importance of DHT in causing nodular hyperplasia is supported by clinical observations in which an inhibitor of 5α-reductase such as finasteride is given to men with this condition. (wikipedia.org)
  • patients
  • In a retrospective analysis of 388 patients with HF and benign prostatic hypertrophy receiving alpha blockers, including prazosin, terazosin, doxazosin, or tamsulosin, Dhaliwal and colleagues found no significant increase in all-cause mortality and HF re-hospitalization in those also receiving β-blockers. (wikipedia.org)
  • mainly
  • In comparison with the few spermatozoa expelled together with mainly seminal vesicular fluid, those expelled in prostatic fluid have better motility, longer survival and better protection of the genetic material. (wikipedia.org)
  • known
  • This typically arises from the inferior vesicle artery (also known as the prostatic artery), but may have supply from the superior vesicle, the internal pudental or obturator branches as well. (clinicaltrials.gov)